"Targeting HIV-1 Nef Functions: Inhibitor Development and Structural Characterization"
Zoom
Heather Blaser
508-999-8587
hblaser@umassd.edu
https://fsu.zoom.us/j/99218698257
Title: Targeting HIV-1 Nef Functions: Inhibitor Development and Structural Characterization
Advisors: Dr. Shuowei Cai, Professor, Department of Chemistry & Biochemistry, University of Massachusetts Dartmouth & Dr. Xiaofei Jia, Associate Professor, Department of Biomedical Sciences, Florida State University
Committee Members: Dr. Catherine Neto, Professor, Department of Chemistry & Biochemistry, University of Massachusetts Dartmouth & Dr. Tracie Ferreira, Professor, Department of Bioengineering, University of Massachusetts Dartmouth
Abstract:
Human immunodeficiency virus type 1 (HIV-1) remains a major global health challenge despite significant advances in antiretroviral therapy (ART). Although ART effectively suppresses viral replication, it does not eliminate persistent viral reservoirs, highlighting the need for alternative therapeutic strategies. The HIV-1 accessory protein Nef plays a critical role in viral pathogenesis. It mediates viral immune evasion by downregulating host cell surface proteins, including CD4 and the antiviral restriction factor SERINC5. Inhibition of Nef-mediated CD4 downregulation may restore cell-surface CD4 expression and enhance antibody-dependent cellular cytotoxicity (ADCC), whereas understanding the structural mechanism of SERINC5 downregulation may provide further insight into Nef-mediated viral immune evasion. This dissertation focuses on the development of inhibitors targeting Nef-mediated CD4 downregulation and the structural investigation of Nef-mediated SERINC5 downregulation.
Chapter 2 describes the development and optimization of a homogeneous time-resolved fluorescence resonance energy transfer (TR-FRET) assay to identify inhibitors of the Nef-CD4 interaction. Two assay formats, FRET(CD4) and FRET(CD4)fusion, were established and demonstrated excellent suitability for high-throughput screening, with Z′ factors of 0.63 and 0.76, respectively. A pilot screen of 640 compounds identified a potential inhibitor, which exhibited concentration-dependent inhibition of the Nef-CD4 interaction.
Chapter 3 focuses on the development and biochemical characterization of CD4-mimetic cyclic peptides designed to disrupt the Nef-CD4 interaction. Using the CD4 cytoplasmic domain as the original template, libraries of cyclic peptides were generated, the members of which differ from one another on sequence compositions. Hits with superior binding affinities toward the Nef-AP2 complex were selected, with dissociation constants ranging from 34 μM to 0.11 μM. Biochemical assays, including size-exclusion chromatography and TR-FRET competition assays, provided preliminary evidence of Nef binding and inhibitory activity for selected cyclic peptides, supporting their potential as inhibitor candidates for further development.
Chapter 4 investigates the structural organization of the Nef-SERINC5-AP2 complex using cryo-electron microscopy (cryo-EM). A Nef-S5L9 fusion construct was successfully expressed, purified, and assembled with a hemicomplex of AP2. Chemical cross-linking stabilized the complex for cryo-EM analysis. Three-dimensional reconstruction yielded a density map at approximately 7.64 Å resolution. Docking of the Nef-AP2 structure revealed additional density that may correspond to S5L9, providing preliminary structural insight into the organization of the complex. However, the limited dataset and resolution prevented confident assignment of this density and determination of the molecular interactions underlying SERINC5 recognition. Nevertheless, this study established an alternative protein construct and sample preparation strategy for future structural investigations.
Collectively, these studies establish a robust screening platform for Nef inhibitor discovery, identify CD4-mimetic cyclic peptides as potential Nef inhibitors, and advance the structural
investigation of Nef-mediated SERINC5 downregulation. These findings contribute to understanding HIV-1 Nef-host protein interactions and support the development of therapeutic strategies targeting Nef-mediated immune evasion.
Zoom Meeting ID: 992 1869 8257